BMO Capital Maintains a Buy on Pfizer Inc (PFE), Keeps the PT

​Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued Growth Stocks to Buy According to Hedge Funds. On September 22, Evan Seigerman from BMO Capital maintained a Buy rating on Pfizer Inc. (NYSE:PFE) with a price target of $30.

​The analyst pointed to the company’s recent acquisition of Metsera. He noted that the deal allows Pfizer Inc. (NYSE:PFE) to re-enter the obesity treatment market and brings promising long-acting GLP-1 and amylin agents. These drugs could compete well against current leaders like Lilly and Novo.

​Moreover, the acquisition includes contingent value rights. This structure reduces the company’s risk while enhancing its market position. Seigerman also likes the valuation of Pfizer Inc. (NYSE:PFE) compared to other companies in the sector. He sees potential for the company to grow revenue and improve margins. These growth prospects are not yet fully recognized by the market.

​Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company focused on discovering, developing, manufacturing, and marketing medicines.

While we acknowledge the potential of PFE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.